Critical Comparison: MacroGenics (MGNX) & The Competition
MacroGenics (NASDAQ: MGNX) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare MacroGenics to similar businesses based on the strength of its earnings, institutional ownership, valuation, analyst recommendations, dividends, profitability and risk.
Risk & Volatility
MacroGenics has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500. Comparatively, MacroGenics’ rivals have a beta of 6.57, suggesting that their average stock price is 557% more volatile than the S&P 500.
Institutional & Insider Ownership
84.5% of MacroGenics shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.3% of MacroGenics shares are owned by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares MacroGenics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares MacroGenics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|MacroGenics||$12.08 million||-$140.86 million||-4.16|
|MacroGenics Competitors||$464.68 million||$167.54 million||-6.57|
MacroGenics’ rivals have higher revenue and earnings than MacroGenics. MacroGenics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent recommendations and price targets for MacroGenics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MacroGenics presently has a consensus price target of $31.56, suggesting a potential upside of 80.83%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.33%. Given MacroGenics’ stronger consensus rating and higher possible upside, equities analysts clearly believe MacroGenics is more favorable than its rivals.
MacroGenics Company Profile
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company’s product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.